Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or Flt1 antagonist for treating cancer

摘要

#$%^&*AU2011201326B220120112.pdf#####C:NRPortblDCCAMT354651 11 DOC-22/03/2011 ABSTRACT "Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or FtI antagonist for treating cancer" The invention relates to agents which possess anti-angiogenic activity and are accordingly useful in methods of treatment of disease states associated with angiogenesis in the animal or human body. More specifically the invention concerns a combination of an antagonist of the biological activity of Angiopoietin-2 and an antagonist of the biological activity of VEGF-A, and/or KDR, and/or Fltl, and uses of such antagonists.